AVOTRES

Serial Number 86029101
606

Registration Progress

Application Filed
Aug 5, 2013
Under Examination
Jul 29, 2014
Approved for Publication
Jun 3, 2014
Published for Opposition
Jun 3, 2014
Registered

Trademark Image

AVOTRES

Basic Information

Serial Number
86029101
Filing Date
August 5, 2013
Published for Opposition
June 3, 2014
Abandonment Date
August 31, 2015
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Aug 31, 2015
Classes
005

Rights Holder

Immune Biological Medicine Industry Development Co.

03
Address
c/o Eaton & Van Winkle LLP
3 Park Avenue, 16th Floor
New York, NY 10016

Ownership History

Immune Biological Medicine Industry Development Co.

Original Applicant
03
New York, NY

Immune Biological Medicine Industry Development Co.

Owner at Publication
03
New York, NY

Legal Representation

Attorney
Robert D. Katz, Esq.

USPTO Deadlines

All Deadlines Cleared

All 5 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

26 events
Date Code Type Description Documents
Aug 31, 2015 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Aug 31, 2015 MAB6 O ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED Loading...
Jan 10, 2015 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jan 8, 2015 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jan 8, 2015 EXT1 S SOU EXTENSION 1 FILED Loading...
Jan 8, 2015 EX1G S SOU EXTENSION 1 GRANTED Loading...
Jul 29, 2014 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jun 3, 2014 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jun 3, 2014 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
May 14, 2014 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Apr 29, 2014 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Apr 29, 2014 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Apr 29, 2014 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Apr 29, 2014 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Apr 29, 2014 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Apr 29, 2014 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED Loading...
Nov 19, 2013 DOCK D ASSIGNED TO EXAMINER Loading...
Nov 19, 2013 CNRT R NON-FINAL ACTION WRITTEN Loading...
Nov 19, 2013 GNRT F NON-FINAL ACTION E-MAILED Loading...
Nov 19, 2013 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Aug 16, 2013 ALIE A ASSIGNED TO LIE Loading...
Aug 16, 2013 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Aug 16, 2013 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Aug 13, 2013 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Aug 13, 2013 PARI I TEAS VOLUNTARY AMENDMENT RECEIVED Loading...
Aug 8, 2013 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Anti-cancer preparations; Diagnostic agents, preparations and substances for medical purposes; Diagnostic preparations for medical purposes; Medical diagnostic reagents; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for the treatment of inflammatory disorders; for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for immunological disorders or cancer using biopharmaceutical or pharmaceutical agents
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005